PMID- 36311486
OWN - NLM
STAT- MEDLINE
DCOM- 20221101
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 2022
DP  - 2022
TI  - Effect of Liraglutide on Serum TSH Levels in Patients with NAFLD and its 
      Underlying Mechanisms.
PG  - 1786559
LID - 10.1155/2022/1786559 [doi]
LID - 1786559
AB  - This study aimed to evaluate the effect of liraglutide on serum 
      thyroid-stimulating hormone (TSH) levels in patients with type 2 diabetes 
      mellitus (T2DM) and explore the underlying mechanisms via bioinformatics 
      analysis. A total of 49 obese/overweight patients with T2DM received liraglutide 
      during outpatient visits or hospitalization in the Department of Endocrinology. 
      Meanwhile, the control group included 49 patients with T2DM but without 
      nonalcoholic fatty liver disease (NAFLD) who were matched for age and sex 
      (baseline from July 2016 to June 2021). Follow-up data on the last use of 
      liraglutide were also retrieved. Age, sex, body mass index (BMI), and duration of 
      diabetes were obtained from the participants' records. All patients were tested 
      for biochemical markers hemoglobin A1c (HbA1c), alanine transaminase, aspartate 
      transaminase, free triiodothyronine, free thyroxine (FT4), and TSH at baseline 
      and follow-up. After adjusting for all factors with a p-value < 0.05, BMI, HbA1c, 
      LDL, FT4, and TSH were identified as significant independent risk factors for 
      NAFLD in the univariate analysis. Following liraglutide therapy (average time 16 
      months), these patients had significantly lower BMI, HbA1c, and TSH but higher 
      high-density lipoprotein (HDL) levels than those in the baseline data (all 
      p < 0.05), and further subgroup analysis stratified by duration of liraglutide 
      use showed that the test for time trends had statistical differences in BMI and 
      TSH but not in HbA1c and HDL. After the therapy, the NAFLD and NASH groups showed 
      significantly decreased TSH levels after liraglutide therapy compared with the 
      corresponding baseline data. Furthermore, the expression of THRB, which encodes 
      TRbeta, was significantly decreased in the NAFLD group, which may explain the 
      thyroid hormone resistance-like manifestation in the clinical findings. In 
      conclusion, liraglutide improves hepatic thyroid hormone resistance in T2DM with 
      NAFLD, and restoration of impaired TRbeta expression in NAFLD is a potential 
      mechanism involved in the process of liraglutide therapy.
CI  - Copyright (c) 2022 JiaoJiao Ye et al.
FAU - Ye, JiaoJiao
AU  - Ye J
AD  - Department of Infectious Diseases, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, Anhui 230001, China.
FAU - Xu, Jing
AU  - Xu J
AD  - Department of Infectious Diseases, The First Affiliated Hospital of USTC, 
      Division of Life Sciences and Medicine, University of Science and Technology of 
      China, Hefei, Anhui 230001, China.
FAU - Wen, WenJie
AU  - Wen W
AD  - Department of Endocrinology, The First Affiliated Hospital of USTC, Division of 
      Life Science and Medicine, University of Science and Technology of China, Hefei, 
      Anhui 230001, China.
FAU - Huang, Bin
AU  - Huang B
AUID- ORCID: 0000-0002-5257-7464
AD  - Department of Endocrinology, The First Affiliated Hospital of USTC, Division of 
      Life Science and Medicine, University of Science and Technology of China, Hefei, 
      Anhui 230001, China.
LA  - eng
PT  - Journal Article
DEP - 20221013
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 839I73S42A (Liraglutide)
RN  - 0 (Glycated Hemoglobin A)
RN  - 9002-71-5 (Thyrotropin)
SB  - IM
MH  - Humans
MH  - *Non-alcoholic Fatty Liver Disease/complications/drug therapy
MH  - Liraglutide/therapeutic use
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glycated Hemoglobin/analysis
MH  - *Thyroid Hormone Resistance Syndrome
MH  - Thyrotropin
PMC - PMC9584744
COIS- The authors declare that they have no potential conflicts of interest.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/02 06:00
PMCR- 2022/10/13
CRDT- 2022/10/31 04:21
PHST- 2022/08/21 00:00 [received]
PHST- 2022/09/29 00:00 [revised]
PHST- 2022/10/03 00:00 [accepted]
PHST- 2022/10/31 04:21 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/02 06:00 [medline]
PHST- 2022/10/13 00:00 [pmc-release]
AID - 10.1155/2022/1786559 [doi]
PST - epublish
SO  - Int J Clin Pract. 2022 Oct 13;2022:1786559. doi: 10.1155/2022/1786559. 
      eCollection 2022.